Search

Displaying results 91 - 100 of 4672 in total
  1. Pathway

    Glibenclamide Action Pathway

    smpdb.ca/view/SMP0000460
    Drug action

    Depolarization causes opening of voltage-gated calcium channels, allowing calcium to enter cell. High intracellular calcium subsequently stimulate vesicle exocytosis and insulin secretion.

    Drugs: ATP · Glyburide · Potassium cation · Calcium
    Enzymes: Voltage-dependent P/Q-type calcium channel subunit alpha-1A, Voltage-dependent L-type calcium channel subunit beta-1
  2. Pathway

    Gliclazide Action Pathway

    smpdb.ca/view/SMP0000461
    Drug action

    Depolarization causes opening of voltage-gated calcium channels, allowing calcium to enter cell. High intracellular calcium subsequently stimulate vesicle exocytosis and insulin secretion.

    Drugs: ATP · Gliclazide · Potassium cation · Calcium
    Enzymes: Voltage-dependent P/Q-type calcium channel subunit alpha-1A, Voltage-dependent L-type calcium channel subunit beta-1
  3. Pathway

    Repaglinide Action Pathway (New)

    smpdb.ca/view/SMP0124704
    Drug action

    In consequence, the increased concentration of calcium results in the stimulation of the calcium-dependent exocytosis of insulin granules. … This results in the depolarization of the beta cell and the opening of the L-type calcium channels.

    Drugs: ATP · Repaglinide · Potassium cation · Calcium
    Enzymes: Voltage-dependent P/Q-type calcium channel subunit alpha-1A, Voltage-dependent L-type calcium channel subunit beta-1
  4. Pathway

    Glimepiride Action Pathway

    smpdb.ca/view/SMP0124722
    Drug action

    Normally SUR1 closes in response to high glucose concentrations, the membrane potential of the cells becomes less negative, the cell depolarizes, voltage-gated calcium channels open, calcium ions enter … the cell, and the influx of intracellular calcium concentration stimulates the secretion of insulin.

    Drugs: ATP · Glimepiride · Potassium cation · Calcium
    Enzymes: Voltage-dependent P/Q-type calcium channel subunit alpha-1A, Voltage-dependent L-type calcium channel subunit beta-1
  5. Pathway

    Chlorpropamide Action Pathway

    smpdb.ca/view/SMP0126141
    Drug action

    This depolarization stimulates calcium ion influx through voltage-sensitive calcium channels, raising intracellular concentrations of calcium ions, which results in the secretion (exocytosis) of insulin

    Drugs: ATP · Chlorpropamide · Potassium cation · Calcium
    Enzymes: Voltage-dependent P/Q-type calcium channel subunit alpha-1A, Voltage-dependent L-type calcium channel subunit beta-1
  6. Pathway

    Glipizide Action Pathway

    smpdb.ca/view/SMP0126142
    Drug action

    This results in the depolarization of the pancreatic beta cell and the opening of the voltage-sensitive calcium channels. … This higher concentration of intracellular calcium ions in beta cells stimulates the secretion (exocytosis) of insulin from the cells. This drug is administered as an extended release oral tablet.

    Drugs: ATP · Glipizide · Potassium cation · Calcium
    Enzymes: Voltage-dependent P/Q-type calcium channel subunit alpha-1A, Voltage-dependent L-type calcium channel subunit beta-1
  7. Pathway

    Dextromethorphan Nicotinic Acetylcholine Antagonism Action Pathway

    smpdb.ca/view/SMP0126451
    Drug action

    They are present in the endoplasmic reticulum of central nervous system neurons, where they regulate calcium and potassium, but the reason for that is not well understood.

    Drugs: Choline · Dextromethorphan · Calcium · Magnesium cation · Acetylcholine
    Enzymes: Voltage-dependent P/Q-type calcium channel subunit alpha-1A, Voltage-dependent L-type calcium channel subunit beta-1
  8. Pathway

    NGX267 Action Pathway

    smpdb.ca/view/SMP0126364
    Drug action

    NGX267 is a muscarinic agonist. It is developed for the treatment of Alzheimer’s disease and has shown the potential to both reduce symptoms and slow disease progression. Due to its mechanism of action, NGX267 may be simultaneously effec...

    Drugs: Choline · Calcium · Magnesium cation · Acetylcholine · Acetic acid · NGX267
    Enzymes: Voltage-dependent L-type calcium channel subunit beta-4, Voltage-dependent L-type calcium channel subunit beta-1
  9. Pathway

    Isoflurophate Action Pathway (new)

    smpdb.ca/view/SMP0126686
    Drug action

    Isoflurophate is a cholinesterase inhibitor used to treat glaucoma, as it acts as a powerful miotic agent constricting the pupil and causing the aqueous fluid to flow out and relieve pressure. It acts by irreversibly binding to acetylcho...

    Drugs: Choline · Isoflurophate · Calcium · Magnesium cation · Acetylcholine · Acetic acid
    Enzymes: Voltage-dependent L-type calcium channel subunit beta-4, Voltage-dependent L-type calcium channel subunit beta-1
  10. Pathway

    Demecarium Action Pathway (new)

    smpdb.ca/view/SMP0126687
    Drug action

    Demecarium is a cholinesterase inhibitor used in the treatment of glaucoma, acting as an indirect parasympathomimetic agent by increasing acetylcholine levels in the synaptic cleft. The mechanism of action is demecarium the drug acts on ...

    Drugs: Choline · Demecarium · Calcium · Magnesium cation · Acetylcholine · Acetic acid
    Enzymes: Voltage-dependent L-type calcium channel subunit beta-4, Voltage-dependent L-type calcium channel subunit beta-1